Business Standard
BS Reporter |
Mumbai:May 4, 2016 Last Updated at 17:48 IST
Copy tiny URL to save and share articles.
The drug, Tildrakizumab, is being developed by Sun Pharmaceutical under license from multi national drug major MSD.
The trials focused on evaluating the efficacy and safety of the under trial drug in patients with moderate-to-severe plaque psoriasis, a skin disorder.
"We are encouraged by these results and the potential to provide a new treatment option to patients with moderate-to-severe plaque psoriasis, a disease that often takes both a physical and emotional toll on their lives," stated Dilip Shanghvi, Managing Director, Sun Pharma.
Over 1,800 patients participated in the trials at more than 200 clinical sites.
Sun Pharma acquired worldwide rights to tildrakizumab for use in all human indications from MSD in exchange for an upfront payment of $80 million.
The drug, Tildrakizumab, is being developed by Sun Pharma under license from MNC drug major MSD
The drug, Tildrakizumab, is being developed by Sun Pharmaceutical under license from multi national drug major MSD.
The trials focused on evaluating the efficacy and safety of the under trial drug in patients with moderate-to-severe plaque psoriasis, a skin disorder.
"We are encouraged by these results and the potential to provide a new treatment option to patients with moderate-to-severe plaque psoriasis, a disease that often takes both a physical and emotional toll on their lives," stated Dilip Shanghvi, Managing Director, Sun Pharma.
Over 1,800 patients participated in the trials at more than 200 clinical sites.
Sun Pharma acquired worldwide rights to tildrakizumab for use in all human indications from MSD in exchange for an upfront payment of $80 million.